NHS rationing bodies refuse to fund treatment which stalls breast cancer A breast cancer drug which stalls disease by three months has been rejected by NHS rationing bodies.
The National Institute of Health and Care Excellence said there was a lack of evidence to prove that the drug called fulvestrant extended lives.
Some trials have suggested it could extend survival by more than five months, for women whose cancer has spread.
But Nice said there were weaknesses in such research. While trials showed the drug stalls the cancer’s growth by around three months, there was a lack of good evidence that this extended survival, they said.
The drug costs £500 a month, compared to costs of just pennies for anastrozole, and letrozole, which are currently prescribed for such cases. The Daily Telegraph
See also:
The National Institute of Health and Care Excellence said there was a lack of evidence to prove that the drug called fulvestrant extended lives.
Some trials have suggested it could extend survival by more than five months, for women whose cancer has spread.
But Nice said there were weaknesses in such research. While trials showed the drug stalls the cancer’s growth by around three months, there was a lack of good evidence that this extended survival, they said.
The drug costs £500 a month, compared to costs of just pennies for anastrozole, and letrozole, which are currently prescribed for such cases. The Daily Telegraph
See also:
- Jab to halt breast cancer rejected by NHS watchdog The Daily Mail
No comments:
Post a Comment